Novartis receives USFDA nod for heart failure drug

10 Jul 2015 Evaluate

Novartis has received nod from the US health regulator for its heart failure treatment tablets - LCZ696 - and the company plans to launch the medicine in India. It will benefit many patients afflicted with heart failure.

The company plans to launch LCZ696 (sacubitril/valsartan) tablets under the brand name 'Entresto' in the US market. The tablets-LCZ696 will reduce risk of death from cardiovascular causes by 20 percent and will offer to patients a much greater opportunity to live longer and stay out of hospital.

Novartis is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.

Novartis Share Price

778.80 0.05 (0.01%)
02-Jan-2026 09:27 View Price Chart
Peers
Company Name CMP
Redington 275.20
Adani Enterprises 2265.00
Amrapali Industries 13.98
Rashi Peripheral 363.15
PDS 371.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×